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Abstract: The body defense mechanism has evolved to protect animals from invading   pathogenic 
microorganisms and cancer. It is able to generate a diverse variety of cells and   molecules capable 
of specifically recognizing and eliminating a limitless variety of foreign   invaders. These cells 
and molecules act together in a dynamic network and are known as the immune system. Innate 
mucosal immunity consists of various recognition receptor molecules, including toll-like 
receptors, NOD-like receptors, and RIG-I-like receptors. These recognition receptor molecules 
recognize various invading pathogens effectively, and generate an immune response to stop 
their entry and neutralize their adverse consequences, such as tissue damage.   Furthermore, they 
regulate the adaptive response in cases of severe infection and also help generate a memory 
response. Most infections occur through the mucosa. It is important to understand the initial 
host defense response or innate immunity at the mucosal surface to control these infections and 
protect the system. The aim of this review is to discuss the effects and functions of various innate 
mucosal agents and their importance in understanding the physiological immune response, as 
well as their roles in developing new interventions.
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Introduction
The mucous membrane that covers the digestive and urogenital tracts, the respiratory 
canal, the eye conjunctiva, the inner ear, and layers of most of the exocrine glands, is a 
strong component of the immune system, with very specialized mechanical and chemi-
cal barriers that either prevent the entry of foreign bodies or facilitate their degradation 
through a series of chemical processes, most of which are yet to be fully clarified. 
The mucosa prevents colonization and invasion by foreign pathogens, and prevents 
any aggravated response of the immune system to such pathogens that could harm the 
organism. This is a rather local but specialized version of the immune system, and is 
well interlinked with the lymphatic system, and thus is known as mucosa-associated 
lymphatic tissue or, in a more functional sense, the mucosal immune system. There 
are various subsets of this broad term, including gut-associated lymphatic tissue, 
bronchus-associated lymphatic tissue, and nasal-associated lymphatic tissue. The 
mucosal immune system has two parts, ie, the innate system and the adaptive system. 
The innate system comprises various recognition molecules and natural killer cells, 
while the adaptive system comprises various antigen-presenting cells and the T and 
B lymphocytes.1
The recognition of foreign bodies at the mucosal surface takes place in a number 
of ways. Cell-intrinsic recognition involves the dendritic cell recognizing cytosolic International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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pathogen-associated microbial patterns (PAMPs) using vari-
ous pattern recognition receptors, followed by the presenta-
tion of pathogens, either by the major histocompatibility 
complex (MHC) Class I pathway (via rough endoplasmic 
reticulum) or the MHC Class II pathway (via autophagy). 
  Signaling by pattern recognition receptors induces costimu-
latory molecules and cytokines that activate T cells. In cell-
intrinsic recognition, the MHC I pathway depends on an 
abundance of antigens, while the MHC II pathway depends 
on autophagy machinery. Cell-extrinsic recognition can 
recognize either pathogenic or infected cells. On encounter-
ing an infected cell, pattern recognition receptors induce the 
secretion of interferons (IFNs) and dendritic cell-activating 
cytokines. This is followed by MHC Class I or II antigen 
presentation. If toll-like receptors are involved in recognition, 
they induce costimulatory molecules and cytokines, thus 
activating the T cell response. On an encounter, pathogen   
toll-like receptors recognize the pathogen and move, along 
with the pathogen, into the cell phagosome where antigen 
processing and presentation occurs only via the MHC 
Class II pathway, followed by secretion of T cell activation 
molecules2–4 (see Figure 1).
The mucosal immune system is unique, being characterized 
by the presence of specific types of lymphocytes which are 
not found in the bloodstream and have a very different type of 
immune reaction, with the presence of the secretory antibody, 
immunoglobulin (Ig)A.5 Another characteristic feature of this 
system is the ability to differentiate, via pattern recognition 
receptors, between a pathogenic particle and a nonpatho-
genic one.6 Toll-like receptors, a class of pattern recognition 
  receptors, are specialized antigen- and adjuvant-sensing 
molecules found on almost all mucosal antigen-presenting 
cells. They not only recognize foreign pathogens, but also 
commensals, and thus maintain a steady-state environment 
inside the gut. Similar molecules, like NOD-like receptors and 
Type C lectins, also provide an immediate response to patho-
gens and tissue damage by recruiting innate immune cells, like 
macrophages and neutrophils, thus triggering tissue repair and 
switching over to adaptive immune mechanisms.7
The gastrointestinal tract is the largest mucosal surface 
in all mammalian systems, and most pathogens try to invade 
the body system through the gut mucosa. Intestinal epithe-
lial cells comprise the most vital part of the gut mucosa 
and regulate the various gut processes, including digestion, 
secretion, absorption, and defense. Their main function is 
the transport of polymeric immunoglobulins produced by 
plasma cells in the lamina propria to the intestinal lumen 
via a receptor-mediated pathway and the recognition of 
foreign matter via pattern recognition receptors.8 They also 
have an important role in antigen presentation, and have the 
dual ability to present both Class I and Class II antigens and 
also secrete immunologically active proteins in response to 
proinflammatory cytokines, thus preventing any damage to 
the intestinal lumen and mucosa.9 In addition, epithelial cells 
express CD14 molecules that bind to lipopolysaccharides 
and also control the interaction between commensals and 
the mucosa.10
The second class of cells in the mucosa basically com-
prises T lymphocytes expressing CD8, CD45RO, integrins, 
and perforins.11 Another specialized class of cells, called 
M cells, found in the mucosal membrane, help absorb anti-
gens and then transport them to Peyer’s patches, followed 
by antigen activation of T cells.12
Innate immunity cells release proinflammatory cytokines 
that subsequently activate the components of the adaptive 
immune system. Specialized epithelial and intraepithelial 
cells also form a part of the mucosa, and maintain a bal-
ance by self-renewal, and also maintain a balance between 
the commensal colonies residing in the mucosa. Migration 
of T and B lymphocytes from the lymph nodes to the com-
mon mucosa has been observed, and is related to activation, 
recirculation, and activation of lymphocytes, and also the 
development of memory lymphocytes. Such movements 
are controlled by specific integrin-type molecules and 
chemokines secreted in the mucosa, including CC chemokine 
ligand 25.13,14 Regulatory T cells secrete lymphokines, includ-
ing interleukin (IL)-10 and transforming growth factor beta 
(TGF-β), that result in oral immunosuppression/tolerance, 
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Figure 1 Pathogen recognition by dendritic cells in mucosa by toll-like receptors 
and RLR and their processing via major histocompatibility complex I and II pathways 
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thus preventing any immune response to food particles during 
ingestion.15 Similar mechanisms are hypothesized to work in 
the colorectal immune response, which has no effect on the 
small intestine, and in the nasal immune response in the upper 
respiratory tract mucosa that is exposed to large amounts of 
nasal and lacrimal secretions.
The populations of various intra-epithelial T lymphocytes 
increase gradually, but markedly, in both germ-free and normal 
mice after birth upon colonization by commensal microbiota, 
and are thus important in controlling their growth and interac-
tion with cells in the local environment of the gut mucosa.11
A study of bronchus-associated lymphatic tissue in 
patients with lung carcinoma showed T cells surrounding B 
cell follicles, and most CD4 T cells also exhibited CD45RO, 
and thus had memory responses as well. All the B cells 
exhibited α4 integrin and L-selectin, while only 43% and 
20% of the total population of T cells showed α4 integrin 
and L-selectin, respectively. In lung mucosa-associated 
disease, there is a strong combined mucosal and systemic 
immune response regulated by CD4-expressing TH2 cells 
and TH1 cells in patients with asthma and tuberculosis, 
respectively.16 L-selectin, a receptor molecule prominent in 
the head and neck mucosa and in the lymph nodes, regulates 
the trafficking of lymphocytes to these sites. Another set of 
molecules, known as α-defensins, regulates the mucosal 
immune system of the gut and prevents microbial invasion at 
the epithelial surface. These are of six types, ie, human neu-
trophil peptides 1, 2, 3, and 4, and human defensins 5 and 6. 
Their counterparts in murine gut-associated lymphatic tissue 
are known as cryptidins. Human defensin 5 is expressed in 
disorders like gastritis, ulcerative colitis, and Crohn’s disease. 
Human neutrophil peptides 1, 2, and 3 are strongly expressed 
in all types of inflammatory bowel disease. Activation of 
α-defensins and cryptidins requires a colocalized molecule 
known as metalloproteinase matrilysin.17
In metalloproteinase matrilysin-mutant mice, there is a 
prominent absence of cryptidins and accumulation of cryp-
tidin precursors. Such mice are much more susceptible to 
ingested pathogens than wild-type varieties. 
Human defensins not only prevent invasion by patho-
gens, but also trigger the influx of different populations of T 
lymphocytes for further adaptive responses. C type lectins, 
like RegIIIγ, are expressed in the intestinal mucosa, have 
antimicrobial properties, interact with bacteria via a pepti-
doglycan mechanism, and aid the recruitment of symbiotic 
bacteria in the intestine.18
Mucosal immunity is directly involved in a number of 
infectious diseases and allergies. In the upper respiratory 
tract, where active influx of IgA and IgM occurs in response 
to any immune aggravation, with some locally produced IgG, 
Waldeyer’s ring exhibits adhesion molecules and various 
chemokine receptors expressed in B lymphocytes present 
there, due to a higher possibility of airborne allergens, which 
are more frequent.19
A general hypothesis that can be made from all the stud-
ies done to date at the mucosa is that innate immunity is the 
true regulator of the immune system. This hypothesis is at 
the basis of almost all mucosal disease, as well as mucosal 
vaccine development.
Mucosal diseases
Because the mucosal surface serves as a portal for many 
infectious diseases, almost all types of pathogens, ie, bacteria, 
virus, fungi, and parasites, cause disease at the mucosa while 
trying to invade the body. Some common mucosal diseases 
caused by a variety of pathogens are described.
The main disease of concern affecting the intestinal 
mucosa is inflammatory bowel disease, in particular, Crohn’s 
disease and ulcerative colitis. Crohn’s disease is a transmural 
inflammation of the bowel at the terminal ileum and right 
colon preferentially, but sometimes also involves the colon, 
rectum, and peritoneal area. The main symptoms are diar-
rhea, abdominal pain, and weight loss, often accompanied 
by extradigestive manifestations, including fever, ulcers, 
arthralgia, and erythema nodosum. About 20% of people 
with Crohn’s disease have a blood relative with some form 
of inflammatory bowel disease, often a brother or sister, 
and sometimes a parent or child. Crohn’s disease can occur 
in people of all age groups, but is more often diagnosed in 
people aged 20–30 years. Ulcerative colitis causes inflam-
mation and ulcers in the top layer of the lining of the large 
intestine. Ulcerative colitis primarily affects the colonic 
mucosa, and the extent and severity of colon involvement 
are variable. In its most limited form, it may be restricted 
to the distal rectum, while in severe cases, the entire colon 
is involved. Both genders are equally affected. In Western 
Europe and in the US, ulcerative colitis has an incidence 
of approximately 6–8 cases per 100,000 and an estimated 
prevalence of approximately 70–150 per 100,000. The 
leading initial symptom of ulcerative colitis is diarrhea with 
blood and mucus, sometimes with pain. Fever and weight 
loss are less frequent. Extraintestinal symptoms can be an 
initial manifestation or can occur later in the course of the 
disease. In proctitis, obstipation can very occasionally be 
the initial symptom. Eighty percent of patients have only 
proctitis or proctosigmoiditis, and only 20% have extensive International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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colitis. The etiology of both Crohn’s disease and ulcerative 
colitis remains unknown, although very recent studies have 
hypothesized multiple factors leading to the disease, ranging 
from tobacco smoking to malnutrition or unhealthy eating 
habits.20,21
Helicobacter pylori is a Gram-negative bacterium that 
colonizes the gastric mucosa and causes chronic gastritis and 
gastric ulcers. The bacterium adheres strongly to the surface 
of gastric epithelial cells without actually invading them. 
H. pylori infection is relatively common worldwide, although 
less than one-quarter of infected individuals progress to the 
development of gastric disease. H. pylori infection is common 
in the US. About 20% of people younger than 40 years of 
age and half of those over 60 years of age have the disease. 
However, most infected individuals do not develop ulcers. 
Whether or not an individual proceeds to a disease state 
may be influenced by any combination of host, bacterial, 
and environmental factors. H. pylori weakens the protective 
mucous coating of the stomach and duodenum, which allows 
acid to get through to the sensitive lining beneath. Both the 
acid and the bacteria irritate the lining and cause an ulcer. 
Serious problems may occur, including perforation (when 
the ulcer burrows through the stomach or duodenal wall), 
bleeding (when acid or the ulcer breaks a blood vessel), and 
obstruction (when the ulcer blocks the path of food trying 
to exit the stomach).22
Diarrhea is the second leading cause of childhood mor-
bidity and mortality worldwide, and each year almost two 
million children under five years of age die from severe 
gastroenteritis. Rotaviruses are the single leading cause of 
diarrhea-related deaths in this age group. It is estimated that 
each year, amongst children younger than five years of age, 
rotaviruses account for 114 million episodes of diarrhea, 
25 million clinic visits, 2.4 million hospital admissions, 
and more than 500,000 deaths worldwide. About 99% of 
rotavirus-associated deaths occur in middle- and low-income 
countries, predominantly affecting infants in the first year 
of life living in socioeconomically deprived rural regions 
of Africa and Asia. In India alone, rotaviruses cause more 
than 120,000 deaths, 400,000 hospital admissions, 5 million 
clinic visits, and 25 million episodes of diarrhea annually. 
One in 250 children from the low-income countries of Africa 
and Asia die from rotavirus gastroenteritis before the age of 
five years. After an incubation period of 1–3 days, rotavirus 
gastroenteritis typically begins abruptly with fever and vom-
iting, followed by watery diarrhea. Less commonly, it may 
present with vomiting and diarrhea only, or even with either 
symptom alone with or without fever. Symptoms usually last 
for 3–8 days, with dehydration, and electrolyte and acid-base 
disturbance as the most serious complications. Compared 
with other enteric pathogens, children hospitalized with 
rotavirus gastroenteritis are more likely to have high fever, 
vomiting, and dehydration. Noroviruses are important patho-
gens in both sporadic cases and outbreaks of gastroenteritis 
in humans. Noroviruses can affect individuals of all ages in 
a variety of settings. The most common acute symptoms are 
diarrhea and nausea followed by vomiting, abdominal pain, 
fever, and fecal incontinence. Various nonspecific symptoms 
are also reported on the first day of illness, with anorexia 
being most frequent, followed by thirst and lethargy, then 
headache and vertigo.23–26
Entamoeba histolytica is a pathogenic organism that is 
widespread throughout the world, but is especially common 
in developing countries, where many people do not have 
access to clean water. The parasite causes invasive disease in 
over 50 million people and an estimated 100,000 deaths per 
year, making it a leading cause of parasitic death in humans. 
Infection with E. histolytica can lead to asymptomatic 
colonization, amoebic colitis, or disseminated extraintes-
tinal disease. The infectious cycle of E. histolytica begins 
with ingestion of the cyst, a nondividing, quadrinucleate 
form that is able to survive in the environment. After inges-
tion, the cyst undergoes excystation in the small intestine 
to produce the proliferative trophozoite form. Trophozoites 
colonize the colon, adhering to the mucous layer by means 
of lectin, which binds colonic mucins. Disease results when 
this mucous layer is penetrated and the trophozoites attack 
the intestinal epithelial cells after entering the mucous layer 
due to a protective, chitin-containing cell wall.27–29
Influenza is a highly contagious acute respiratory dis-
ease caused by infection of the host respiratory tract by the 
influenza virus. The global morbidity and mortality burden 
of influenza is considerable, with an estimated one million 
deaths annually worldwide. In temperate regions, there are 
clear seasonal variations in the occurrence of influenza, 
with a marked peak in the cold winter months. In contrast, 
seasonality is less well-defined in tropical regions, where 
there is high background influenza activity throughout the 
year, with epidemics occurring in the intermediate months 
between the influenza season in temperate countries of the 
Northern and Southern hemispheres. The major limitation of 
current influenza vaccines is that they are strain-specific and 
thus ineffective against new variants of the viruses resulting 
from genetic changes that cause antigenic drifts in hemag-
glutinin or antigenic shifts to another hemagglutinin subtype. 
Administration of vaccines is also limited by the potential International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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for sensitivity to the egg-propagated vaccine and by the fact 
that, as a preventative measure, vaccination cannot provide a 
means of immediate treatment or prophylaxis.30,31
Human papilloma virus (HPV) infections occur all over 
the world. HPV is associated with a plethora of clinical condi-
tions, ranging from innocuous lesions to cervical cancer. HPV 
infects the skin and mucosa, and may induce the formation of 
both benign and malignant tumors. The infection starts when 
the virus penetrates the new host through micro injury. The 
development of the incubation phase into active expression 
depends on three factors, ie, cell permeability, virus type, 
and host immune status. Mucosal HPV infects and replicates 
in the mucous membranes (genital, oral, and conjunctival 
papillomas), and induces epithelial proliferation. In recent 
years, HPV has become one of the most common sexually 
transmitted diseases in both men and women worldwide. 
Cervical cancer is also one of the most common cancers in 
women. Recurrent respiratory papillomatosis is a benign, 
often multifocal neoplasm. A potentially fatal manifestation 
of HPV infection, recurrent respiratory papillomatosis is 
characterized by multiple warty excrescences on the mucosal 
surface of the respiratory tract.32,33
Molecules of mucosal immunity
Mucosal immune regulation is activated and induced by 
various pathways utilizing a variety of biomolecules, 
including lectin, selectins, integrins, NOD-like receptors, 
pyrin domain-containing NOD-like receptors (NALPs), and 
retinoic acid-inducible protein-1 (RIG-I)-like receptors, with 
the most important being the toll-like receptors.
Mammalian toll-like receptors are a class of pattern rec-
ognition receptors that play a major role in the initiation of 
innate mucosal immune responses and the following adaptive 
immune responses to microbial pathogens.   Activation of the 
toll-like receptor signaling pathway leads to the expression of 
numerous genes regulating host defense, including inflamma-
tory cytokines, chemokines, antigen-presenting molecules, 
and costimulatory molecules. These evolutionarily conserved 
receptors, homologs of the Drosophila toll gene, recognize 
highly conserved structural motifs only expressed by PAMPs. 
PAMPs are very different from host cell-surface molecular 
patterns, and toll-like receptors have unique recognition abil-
ity for PAMPs. TLR1, TLR2, TLR4, and TLR6 recognize lipid 
microbial ligands, TLR3, TLR7, TLR8, and TLR9 recognize 
nucleotide ligands, TLR5 recognizes protein ligands, and 
uropathogenic organisms are recognized by TLR11.1
Toll-like receptors are Type 1 transmembrane pro-
teins characterized by an extracellular domain containing 
  leucine-rich repeats and a cytoplasmic tail that contains a 
conserved region called the toll/IL-1 receptor domain. The 
structure of the extracellular domain of TLR3 was recently 
revealed by crystallography studies as being a large horse 
shoe shape. Stimulation of toll-like receptors by PAMPs 
initiates signaling cascades that involve a number of pro-
teins, including myeloid differentiation primary response 
gene (88), toll/IL-1 receptor domain-containing adapter-
inducing IFN-β, and IL receptor-associated kinase.1 These 
signaling cascades lead to the activation of transcription 
factors, such as activator protein-1, nuclear factor kappa B 
(NFκB), and IFN regulatory factors, inducing the secretion 
of   proinflammatory cytokines and effector cytokines that 
direct the adaptive immune response. IL receptor-associated 
kinase-4 then activates IL receptor-associated kinase-1 by 
  phosphorylation. Both IL receptor-associated kinase-1 and 
IL receptor-associated kinase-4 leave the myeloid differentia-
tion primary response gene (88)-toll-like receptor complex 
and associate temporarily with TNF receptor-associated 
factor (TRAF)6, leading to its ubiquitination. Bcl10 and 
MALT1 form oligomers that bind to TRAF6, and promote 
TRAF6 self-ubiquitination.   Following ubiquitination, TRAF6 
forms a complex with TGF-β activated kinase (TAK)2/
TAK3/TAK1, inducing TAK1 activation. TAK1 is then 
coupled to the inhibitor of kappa B kinase gamma complex, 
which includes the scaffold protein, nuclear factor kappa B 
essential modulator, leading to the phosphorylation of IκB 
and subsequent nuclear localization of NFκB. Activation of 
NFκB triggers the production of proinflammatory cytokines, 
such as tumor necrosis factor alpha (TNF-α), IL-1, and IL-12, 
which direct the adaptive immune response.34–36
In one study, it was found that the expression pattern 
and function of toll-like receptors in different murine B cell 
subsets including follicular, marginal zone, B-1, and Peyer’s 
patches, were different. B cell subsets express all known 
toll-like receptors, except TLR5 and TLR8. Strong prolif-
eration and antibody secretion was recorded on stimulation 
by different toll-like receptor ligands, particularly ligands to 
TLR1 and 2, TLR2 and 6, and TLR4, 7, and 9. Marginal zone 
B cells have a similar pattern of toll-like receptor expression 
and response. However, B-1b cells do not respond strongly 
to TLR2 ligands. In contrast, Peyer’s patch B cells respond 
strongly to TLR2, 6, and 7 ligation, but poorly to ligands 
for TLR9 and 4. Follicular B cells that stimulate the T cell-
dependent immune response express and secrete antibodies 
to IgG3 and IgM in response to a variety of toll-like receptor 
agonists in vitro. An experiment done with cells of gut-
  associated lymphatic tissue revealed strong expression of International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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TLR9   specifically in Peyer’s patches and mesenteric lymph 
nodes. In the Peyer’s patches they were prominent on dendritic 
cells, B cells, follicle-associated epithelium, and M cells. 
TLR9 confers a wide range of innate immune defenses against 
foreign oligonucleotides derived from bacteria.37
It was found that there was a high upregulation of 
costimulatory molecules in Shigella dysenteriae porin, such 
as C80 and CD86, followed by a marked increase in IgA 
secretion. These cells were found to express TLR2 and TLR6 
for the detection of porin, and can thus be directly correlated 
with mucosal regulation in the case of Shigella infection.38 
Induction of TLR2 by synthetic Pam3CysSK4 in intestinal 
mucosa demonstrated a tight junction-associated barrier 
assembly preventing stress-induced damage via the induction 
of Akt-mediated cell survival using the myeloid differentia-
tion primary response gene (88). Inflammatory stress-like 
colitis results in breakage of tight junctions in intestinal cells, 
while treatment with TLR2-PCSK4 effectively restores tight 
junction integrity and suppresses mucosal inflammation, 
thus providing a way to use toll-like receptors to modulate 
mucosal injury.39 Shigella infection induces the production 
of NFκB and IL-8 in intraepithelial cells and is mediated by 
NOD1.40 It has also been established that Type I fimbriae on 
Shigella are detected by toll-like receptors.41
Ethanol intake causes great stress to the intestinal mucosa 
and damages epithelial cells. A study in C57BL/6J mice 
with ethanol injury demonstrated the expression of TLR4 
following cyclo-oxygenase-2 and prostaglandin E2 expres-
sion, that was further followed by expression of macrophage 
inflammatory protein-2. Thus TLR4 can have a protective 
role in ethanol poisoning of the gut.42 It was demonstrated in 
a murine study of Helicobacter-dependent colitis that mice 
lacking TLR4 showed low expression of IL-10 and thus had 
dysregulation in T cell functioning and lack of homeostasis 
in mucosal cells.43 In another study, using V-TLR4 transgenic 
mice, it was demonstrated that TLR4 has a role in the recruit-
ment of B cells in the lamina propria of the mucosa and also 
upregulates the expression of IgA and IgA-mediated class 
switching of B cells.44 Expression of TLR5 and TLR9 in the 
apices of gastric epithelial cells due to H. pylori infection 
was detected, although this expression was lost in H. pylori 
gastritis.45 TLR5 was shown to detect H. pylori flagellin, 
although this reaction has low immunogenicity.46 Similarly, 
heat shock protein 60 of H. pylori induces activation of TLR2 
and 4, resulting in upregulation of NFκB and IL-8 secretion 
in gastric epithelial cells.47
Elevation of TLR4 expression in epithelial cells of the 
colon has been observed in ulcerative colitis and Crohn’s 
disease, and Asp299Gly and Thre399Ile polymorphisms 
have been correlated with development of these diseases.48 
Upregulation of TLR2 expression in colitis has been observed 
in mice.27 It has also been found in inflammatory bowel 
disease that flagellin-specific antibodies are present in high 
amounts in serum, which links this condition with TLR5.49 
Intestinal myofibroblasts were shown to express TLR2 and 
TLR4 in response to lipopolysaccharide and lipoteichoic 
acid, and were linked to the development of fibrosis related 
to Crohn’s disease.50 Various toll-like receptors of the enteric 
mucosa are known to work alongside NOD2, and control 
inflammatory bowel disease with excessive expression of 
NFκB.51 In the event of E. histolytica infection, neutrophil 
influx to the infection site followed by IL-8 expression was 
identified a long time ago, and later found to be a TLR2- 
and TLR4-dependent mechanism induced by lipopeptide 
phosphoglycan from E. histolytica.52,53
Commensal-dependent colitis is a condition that mostly 
arises due to deficiency of the anti-inflammatory and immune 
tolerance pathways. In a study carried out in IL-10-mutant 
and IL-2-mutant mice, it was observed that in the absence 
of toll-like receptor signaling pathways, both these mutant 
strains developed commensal-dependent colitis due to a 
possible lack of innate immune regulation.54
TLR4 was shown to be the immediate responder to 
Salmonella infection while TLR2 was linked to a later 
response.55 Salmonella flagellin has been shown to induce 
TLR5 activation in intestinal epithelial cells.56 Studies in 
TLR4-mutant mice have confirmed the role of TLR4 in 
infection control and production of TNF-α and several other 
chemokines.57 Salmonella-susceptible mice were shown 
to be deficient in TLR5, and this was linked to the SPI2 
pathogenicity island and SopE2 guanine exchange factor 
in Salmonella.58,59 Salmonella typhi was shown to inhibit 
TLR4 and TLR5 responses, and such infection were unable 
to produce IL-8 or neutrophil activation.60 Resolution of 
primary Salmonella infection, the major causative agent 
of typhoid fever, resulting in enteric bleeding from Peyer’s 
patches, was demonstrated to be controlled by the expression 
of a toll/IL-1R domain-containing adaptor protein through 
downstream signaling via TLR1, 2, 4, and 6.61
A common cause of enteric diarrhea is Escherichia coli, 
the lipopolysaccharide of which is readily recognized by 
TLR4 of intestinal epithelial cells.62 In the event of infec-
tion by pathogenic strains, it was found that TLR5 induced 
activation of NFκB and IL-8 production by intraepithelial 
cells.63 E. coli Type 2 enterotoxin was shown to activate TLR2 
through an interaction of its B subunit.64 It is also established International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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that fimbriae on E. coli activates TLR2 and TLR4 and causes 
inflammation, followed by IL-8 secretion.65
It has been shown that TLR9-deficient mice have upregu-
lation in the population of CD4Foxp3 regulatory T cells 
(T-regs) and a reduction in the expression of IL-17- and 
IFN-γ-producing effector T cells. In such strains of mice, 
engagement of TLR9 from hematopoietic-derived cells 
controlled the T-reg population and gut priming for the 
immune response to Encephalitozoon cuniculi infection.66 
Studies of total parenteral feeding showed upregulation of 
various toll-like receptors in the intestinal mucosa to prevent 
bacteria-mediated septic shock arising from   IFN-γ-mediated 
epithelial cell apoptosis due to lack of enteric feeding. The 
major toll-like receptors involved were TLR4, TLR5, TLR7, 
and TLR9.67 A toll-like receptor study in goats (Capra hircus) 
revealed expression of all toll-like receptors in peripheral 
blood mononuclear cells, as well as lung mucosal lympho-
cytes, with high amounts of TLR10. TLR3, 4, and 10 were 
expressed at lower levels in the uterine and jejunal mucosa, 
while the mucosa of the uterus and skin expressed high 
TLR6 levels.68
The detection of viral influenza has been linked to TLR3, 
7, and 8 for a long time. A case study in rat H3N2 influenza 
showed stimulation of Type 1 IFN, TNF-α, IL-1, and IFN-γ 
by TLR7 and TLR8. Prophylactic administration of these 
toll-like receptors suppresses viral titers in the lung with 
local IFN secretion, hinting at the potential prophylactic 
and/or therapeutic use of these toll-like receptors.69 Another 
study of Haemophilus influenza in mice demonstrated the 
role of TLR4 in intranasal immunization by activating the 
TH1 response followed by mucosal IgA and IgG secretion, 
all of which were absent in TLR4-mutant mice.70 It was also 
shown in another study that cigarette smoke mixed with 
double-stranded DNA induces expression of RANTES (regu-
lated on activation normal T cell expressed and secreted) in 
patients suffering from chronic rhinitis, followed by activa-
tion of TLR3, leading to high levels of human β-defensin 2, 
while cell activation was also upregulated.71 Nasal mucosa 
inflammation has been reported to be mediated by TLR4 
via a local TH1 and TH2 response and upregulation of IL-10. 
This   TLR4-mediated activation is induced by lipopoly-
saccharide and expression of the TLR4 receptor by CD3 
T cells.72 Smooth muscle cells in human airways have been 
shown to express all toll-like receptors. TNF-α and double-
stranded RNA were found to be the most potent inducers of 
TLR2 and TLR3, and along with these two cytokines, IFN-γ 
helped activation of TLR4. Toll-like receptor activation led 
to the release of IL-8 and eotaxin. When Dexamethasone is 
  administered with IFN-γ and TNF-α, a strong TLR2 expres-
sion is induced. Together, TLR2, 3, and 4 were found to be 
major activators of chemokine release and mucosal tolerance 
in human airways.73 Epithelial nasal polyp cells were found to 
express TLR3 strongly on induction by double-stranded RNA 
and then mediated very strong proinflammatory responses 
via the secretion of RANTES, IP-10, IL-8, and granulocyte-
macrophage colony-stimulating factor. Similar studies with 
lipopolysaccharide also mediated similar responses but were 
comparatively weaker.74 A study of bovine nasal-associated 
lymphatic tissue infected with foot and mouth disease virus 
demonstrated high expression of TLR4 mRNA from the 
dorsal soft palate cells in the acute stages of the disease, 
along with strong expression of mRNA for IFN-α, with some 
expression of IFN-γ, IL-1α, TNF-α, and IL-2.75
A study of airway epithelial cells in cystic fibrosis 
showed high expression of TLR2 in diseased cells on induc-
tion and mediated proinflammatory responses in the airway 
mucosa.76 Stimulation of lung mucosal TLR2 and TLR6 by 
MALP-2 showed secretion of IL-8 and macrophage inflam-
matory protein-Iβ and enhances phagocytosis.77 Patients 
suffering from chronic rhinosinusitis with nasal polyps 
exhibited high expression of TLR2 followed by induction 
of high quantities of macrophage inflammatory protein-α, 
RANTES, and granulocyte-macrophage colony-stimulating 
factor.78 The virulence of Group B Streptococcus is mainly 
due to the PBP1a protein required for cell wall synthesis and 
encoded by the ponA gene. An experiment in TLR2-mutant 
mice using two different strains of Group B Streptococcus, 
ie, wild-type and ponA-mutant, revealed that TLR2-mutant 
mice were more susceptible to infection by both strains 
of Group B Streptococcus, indicating the involvement of 
TLR2 in the immune response to Group B Streptococcus 
infection.79 TLR2 and TLR4 show strong expression in the 
middle ear of the rat, and thus have a specific role in the 
detection of the airborne pathogens that usually invade 
the ear mucosa and lead to otitis.80 It was found that oral 
mucosal Langerhans cells express TLR4, and stimulation 
of TLR4 showed expression of coinhibitory molecules, such 
as B7-H1 and B7-H3, and downregulation of the costimu-
latory molecule, CD86, while there was a high increase in 
IL-10 secretion followed by the induction of TGF-β1, Foxp3, 
IFN-γ, and IL-2 in T cells. Thus, TLR4 has great importance 
in oral tolerance via Langerhans cells.81
It has been established that toll-like receptors have a role 
in activating both the cellular and humoral immune response 
in Candida albicans infection, along with C type lectin 
  receptors.82 Gingival epithelial cells showed   expression of International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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TLR2, TLR4, and TLR6, with the production of IL-6, and 
IL-8, and human β-defensins 1 and 2 in the oral mucosa. 
In the same study, it was found that a quorum-sensing 
  molecule, farnesol, that regulates the virulence of C. albicans, 
had a synergistic effect in the production of these cytokines, 
along with TLR2, TLR4, and TLR6.83 TLR2 and soluble 
CD14 expression was found to be unregulated in the oral 
mucosa in diseases such as oral lichen planus and burning 
mouth syndrome. These molecules are present in saliva, and 
thus, can be used as biomarkers to give an indication of such 
diseases. However, the expression of TLR2 was found to be 
lowered in oral mucosa epithelial cells.84
Papillomavirus is a great threat to the mucosal membrane 
because it invades the human body through the mucosa and 
is a potential cause of cancer at a number of sites, includ-
ing the vulva, uterus, intestine, and anus. TLR4 can be 
used as a biomarker to study papillomavirus infection. In a 
bovine study, infection with the E7 and E2 strains of bovine 
papillomavirus-1 was demonstrated to reduce expression 
of TLR4 in fibroblasts significantly.85 The human fallopian 
tube is also lined by mucosa and exhibits mucosal tolerance 
against several viral infections. Epithelial cells of the fallo-
pian tube express TLR1-9. These cells, when treated with a 
TLR3 agonist, showed upregulation of IL-8, TNF-α, human 
β-defensin 2, and IFN-β, and also induced TLR2, TLR3, and 
TLR7.86 Viral infection caused by rotavirus, calicivirus, and 
adenovirus of the gut is usually sensed by TLR3 and TLR8. 
Surface TLR3 has been shown to interact with rotaviral 
double-stranded RNA. Single-stranded RNA viruses are 
usually detected by TLR7 and TLR8.87,88
TLR2 expressed in trophoblast cells of the human pla-
centa has been linked to disorders such aschorioamnionitis. 
  Localized expression of TLR2 in cytotrophoblast and syncy-
tiotrophoblast mucosal cells and decidual stromal cells was 
shown to be decreased in chorioamnionitis.89 Recent research 
has also shown a link between TLR5 expressed in gut mucosa 
and obesity-related metabolic disorders. TLR5-deficient mice 
exhibited hyperphagia, hyperlipidemia, insulin resistance, 
and hyperadiposity.90 In one study, Staphylococcus aureus-
mediated allergic conjunctivitis of the eye was linked to 
TLR2, with high production of IL-4, IL-5, IL-13, and eotaxin, 
mediated by a TH2 response, while TLR2-mutant mice failed 
to exhibit any of these responses.91 In a study of TLR4 in the 
vaginal mucosa of pregnant women, it was found that a single 
nucleotide polymorphism in TLR4 (896 A . G) resulted in 
a TLR4 variant causing high vaginal pH, leading to infection 
by Gardnerella vaginalis and some anaerobic Gram-negative 
rods, while women without this polymorphism were immune 
against such infection.92 A study of vaginal Trichomonas vagi-
nalis infection indicated the activation of TLR4 via secretion of 
proinflammatory cytokines, in particular TNF-α. This resulted 
in a heavy influx of leukocytes to the infection sites.93
A general conclusion that can be drawn from the aforego-
ing observations is that all the different pattern recognition 
receptors and molecules of innate mucosal immunity are the 
first to encounter and recognize a pathogen or antigen, and 
they further induce proinflammatory cytokine production, 
leading to adaptive immunity.
NOD-like receptors constitute a recently identified 
family of intracellular pattern recognition receptors, which 
contains more than 20 members in mammals. NOD-like 
receptors are characterized by tripartite-domain   organization, 
with a conserved nucleotide binding oligomerization 
domain and leucine-rich repeats. NOD1 and NOD2 detect 
specific motifs within peptidoglycans. NOD1 senses 
 D - γ-glutamyl-meso-DAP dipeptide which is found in the 
peptoglycans of all Gram-negative and some Gram-positive 
bacteria, whereas NOD2 recognizes the muramyl dipep-
tide structure found in almost all bacteria.94,95 NOD1 and 
NOD2 signal via receptor-interacting serine/threonine-  protein 
kinase 2 (RIPK2). RIPK2 mediates ubiquitination of the 
inhibitor of kappa B kinase gamma, leading to activation of 
the receptor activator of NFκB and the production of inflam-
matory cytokines, including TNF-α and IL-6. In addition to 
the NFκB pathway, stimulation of NOD1 and NOD2 induces 
the activation of mitogen-activated protein kinases.   Studies 
have shown the involvement of caspase-recruiting domain-
  containing protein (CARD)9 in the selective control 
of NOD2-dependent p38 and c-Jun N-terminal kinase 
signaling.96–98 Genetic variations in NOD2 are associated 
with Crohn’s disease.99 Several NOD1 polymorphisms are 
linked with the development of atopic eczema and asthma.100 
NOD2 is required for the expression of an antimicrobial 
peptide, cryptidin, found in the gastrointestinal mucosa.98 
NOD1-deficient mice are highly susceptible to infection with 
H. pylori, whereas NOD2-deficient mice are more susceptible 
to oral infection with Listeria monocytogenes.101
NOD2 deficiency results in abnormal development 
and function of Peyer’s patches in mice. This phenotype is 
  Peyer’s patch-specific and not apparent after birth but pro-
gresses with time, having been observed for up to 52 weeks. 
Peyer’s patches in NOD2-deficient mice are larger than in 
controls, with increased numbers of both M cells and CD4+ 
T cells. Knockout mice exhibit increased translocation of 
yeast and bacteria across Peyer’s patches and higher concen-
trations of TNF-α, IFN-γ, IL-12, and IL-4.102International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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Pyrin domain-containing NOD-like receptors play a key 
role in the regulation of caspase-1 by forming a multiprotein 
complex known as the “inflammasome”. Caspase-1 partici-
pates in the processing and subsequent release of proinflam-
matory cytokines, including IL-1β and IL-18. At least two 
types of NALP inflammasomes have been identified, ie, the 
NALP1 inflammasome comprising NALP1, nucleotide-
binding oligomerization domain, leucine-rich repeat and 
pyrin domain containing protein 1, CARD7, ASC (apop-
tosis-associated speck-like protein containing a CARD), 
caspase-1 and caspase-5, and the NALP3 inflammasome 
containing NALP3 (NLRP3, cryopyrin, cold-induced auto-
inflammatory syndrome 1), ASC, cardinal, and caspase-1. 
Activation of caspase-1 induced by NALP3 appears to be 
toll-like receptor-independent, whereas secretion of mature 
IL-1β seems to require two stimuli involving the toll-like 
receptor and NALP3. The first stimulus, a toll-like receptor 
ligand, such as lipopolysaccharide, triggers the generation of 
pro-IL-1β, while the second, a stimulus such as adenosine 
triphosphate, induces oligomerization and inflammasome 
assembly. A murine variant of NALP1 (NALP1b) was shown 
to respond to the anthrax toxin, suggesting an engagement of 
the NALP1 inflammasome in the immune response to Bacil-
lus anthracis infection. NALP3 mediates caspase-1 activa-
tion in response to a wide variety of bacteria, including L. 
monocytogenes and S. aureus.103–105
RIG-I-like receptors (also known as Ddx58) contain 
RIG-I-like helicases, which are a family of cytoplasmic RNA 
helicases that are prominent in antiviral responses. RIG-I and 
melanoma differentiation-associated gene 5 (MDA-5) sense 
double-stranded RNA, a replication intermediate for RNA 
viruses, leading to the production of Type IIFNs in infected 
cells.106,107 Upon recognition of double-stranded RNA, they 
are recruited by the adaptor IPS-1 to the outer membrane of 
the mitochondria, leading to the activation of several tran-
scription factors, including IFN regulatory factors 3 and 7, 
as well as NFκB. IFN regulatory factors 3 and 7 control the 
expression of Type I IFNs, while NFκB regulates the produc-
tion of inflammatory cytokines. Interferon regulatory factor 3 
and 7 activation involves TRAF3, NAK-associated protein 1, 
TANK (TRAF family member-associated NFκB activator), 
and the protein kinase, TANK-binding kinase 1 (TBK1) or 
IκB kinase epsilon.108–110 Experiments in RIG-I- and MDA-5-
deficient mice have demonstrated that conventional dendritic 
cells, macrophages, and fibroblasts isolated from these mice 
have impaired IFN induction after RNA virus infection.111 
RIG-I disruption in mice resulted in reduced body weight 
caused by severe damage and inflammatory infiltration into 
the colonic mucosa. The number of Peyer’s patches was 
significantly reduced in RIG-I-deficient mice, and RIG-I 
was found to control the transcriptional activity of G αi2, a 
negative regulator of T cell responses, which may mediate 
the modulatory effects of RIG-I.112,113
The β-defensins are a family of antimicrobial peptides 
that are diversely expressed on mucosal surfaces, and in air-
ways and submucosal gland epithelia. These small cationic 
peptides are products of individual genes and demonstrate 
broad-spectrum activity against bacteria, fungi, and some 
enveloped viruses. Their expression in airway epithelia is 
mostly induced by bacterial peptides or proinflammatory 
cytokines. Β-defensins also act as chemokines for adaptive 
immune cells, including immature dendritic cells and T cells 
via the CCR6 receptor, and provide a link between innate 
and adaptive immunity.114 Lipocalin is a more recently identi-
fied mucosal molecule that responds to bacterial enterobactin 
and inhibits the colonization of Klebsiella pneumoniae fol-
lowed by induction of IL-8 from cultured respiratory cells.115 
This is followed by a strong influx of neutrophils to the site 
of infection. Specialized molecules known as cathelicidins, 
a type of defensin, also harbor the apical granules of epithelial 
cells and have shown antimicrobial activity in preventing the 
entry of larger pathogens. They also act as a bridge between 
innate and adaptive immunity by chemotactically attracting 
dendritic cells and T cells in the presence of severe immune 
aggravation.116
A case study of avian infectious bronchitis revealed 
potent TH1 adaptive immunity accompanied by IL-β 
activation after primary immunization, with strong activa-
tion of T cells and IgA upregulation, and a local memory 
response governed by IgG at the bronchial mucosal surface 
after second immunization.117 TGF-β in the gut is known 
to suppress mucosal inflammation and to heal damaged 
mucosa by upregulating the deposition of extracellular 
matrix in the mucosal mesenchymal cells. It was found 
that in smoking-  related chronic obstructive pulmonary 
disease, the population of mucosal mast cells showed a 
large increase, with altered expression of TGF-β, CD88, 
and renin. Conversely, in acute necrotizing pancreatitis, the 
total mast cell population in the gut was found to decrease. 
Antigen-processing in the gut is a well orchestrated pro-
cess whereby M cells lacking the MHC Class II pathway 
take up foreign antigens through their irregular microvilli, 
transport them to follicular areas where they are processed 
by dendritic cells, and then IgA-secreting plasma cells are 
directed to produce IgA. Dimeric secretory immunoglobulin 
IgA prevents bacteria from adhering to the mucosa and their International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
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further penetration into local cells. IgA has resistance to 
proteolysis and helps transport bactericidal chemicals like 
lactoferrin and lactoperoxidase to the bacterial   surface.118 
A study of trachoma infection of the eye mucosa revealed 
a high concentration of proinflammatory   cytokines, 
such as TNF-α, which were instrumental in attracting 
and activating neutrophils, and low levels of TH1 and TH2 
cytokines were observed in chronic trachoma. Conversely, 
prolonged production of TNF-α and IL-β together was asso-
ciated with a reduction in the IL-1Ra inhibitory mechanism. 
Furthermore, there was the IL-2 class of cytokines were 
highly involved, including IL2, IL2-R, and IL-15.119
Conclusion
Innate mucosal immunity, although not well-studied to date, 
plays a significant role in pathogen trafficking in the body. 
It recognizes pathogens using its various molecules, and 
triggers cascades of signals to eliminate the foreign body, 
induce tissue repair, and further trigger the adaptive immune 
response. Innate mucosal immunity has its own special mem-
ory stores in the form of pattern recognition receptors which 
are heritable and highly specialized. Each pattern recogni-
tion receptor has the capability to distinguish a PAMP and, 
unlike the adaptive response, is genetic and evolutionarily 
conserved, thus making mucosal immunity the primary line 
of defense in almost all mammalian body systems. Similarly, 
mucosal vaccines trigger an innate immune response as a 
starting signal, which leads to adaptive memory, giving rise 
to specific immunity against diseases.
After skin, mucosal surfaces are the largest area of host-
pathogen interaction in mammalian systems. The prospect of 
using the mucosal route for vaccination is increased by the 
fact that almost all infection either begins at or encounters this 
route. Most gastrointestinal, respiratory, urinary, and sexually 
transmitted diseases use the mucosal route for primary and 
subsequent infection. Vaccines are being developed to pre-
vent the pathogen from attaching or colonizing the mucosal 
surface or their subsequent penetration and replication. The 
primary role of vaccines is to provide strong stimulation of 
IgA that further controls the adaptive immune response. Due 
to bystander suppression, mucosal tolerance can be activated 
using T-regs to produce suppressive cytokines.120 This is 
primarily seen in human systems to prevent self-antigenic 
responses. It has been observed that nasal vaccines stimulate 
T-regs to produce IL-10, while oral vaccines stimulate T-regs 
to produce TGF-β. Increased doses had been shown to deplete 
the population of killer T cells and even higher doses cause 
their apoptosis.121
Innate mucosal immunity and mucosal vaccine devel-
opment based on pattern recognition receptors has been a 
neglected area of research for years. However, recent research 
has given an idea of the involvement of innate mucosal immu-
nity in different defense mechanisms, and has paved the way 
for ongoing research in this area. Mucosal pattern recognition 
receptor pathways, pattern recognition receptor structure-
activity relationships, development of new mucosal adjuvant 
and pattern recognition receptor mimetics, are currently hot 
topics in mucosal immunity research. In this review, we have 
attempted to establish the importance of innate immunity 
which may lead to the development of future therapeutics 
for better disease management and control.
Acknowledgments
The authors would like to thank the Department of Atomic 
Energy, Science and Technology and the Department of Bio-
technology, Government of India, for financial assistance.
Disclosure
The authors report no conflicts of interest in this work.
References
  1.  Mestecky J. Mucosal Immunology. 3rd ed. San Diego, CA: Academic 
Press; 2005.
  2.  Stetson DB. Connections between antiviral defense and autoimmunity. 
Curr Opin Immunol. 2009;21:244–250.
  3.  Blander JM, Medzhitov R. Toll-dependent selection of microbial 
antigens for presentation by dendritic cells. Nature. 2006;440: 
808–812.
  4.  Stetson DB, Ko JS, Heidmann T, Medzhitov R. Trex1 prevents cell-
intrinsic initiation of autoimmunity. Cell. 2008;134:587–598.
  5.  Phalipon A, Cardona A, Kraehenbuhl JP, Edelman L, Sansonetti PJ, 
  Corthesy B. Secretory component: A new role in secretory   IgA-mediated 
immune exclusion in vivo. Immunity. 2002;17:107–115.
  6.  Akira S, Hemmi H. Recognition of pathogen-associated molecular 
patterns by TLR family. Immunol Lett. 2003;85:85–95.
  7.  Medzhitov R, Janeway C Jr. Innate immune recognition: Mechanisms 
and pathways. Immunol Rev. 2000;173:89–97.
  8.  Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models 
of inflammation. Annu Rev Immunol. 2002;20:495–549.
  9.  Bland PW. Mucosal T cell-epithelial cell interactions. Chem Immunol. 
1998;71:40–63.
  10.  Funda DP, Tuckova L, Farre MA, Iwase T, Moro I, Tlaskalova-
  Hogenova H. CD14 is expressed and released as soluble CD14 by 
human intestinal epithelial cells in vitro: Lipopolysaccharide activation 
of epithelial cells revisited. Infect Immun. 2001;69:3772–3781.
  11.  Hayday A, Theodoridis E, Ramsburg E, Shires J. Intraepithelial 
  lymphocytes: Exploring the Third Way in immunology. Nat Immunol. 
2001;2:997–1003.
  12.  Fujihashi K, Kato H, van Ginkel FW, et al. A revisit of mucosal IgA 
immunity and oral tolerance. Acta Odontol Scand. 2001;59:301–308.
  13.  Stagg AJ, Kamm MA, Knight SC. Intestinal dendritic cells 
increase T cell expression of alpha4beta7 integrin. Eur J Immunol. 
2002;32:1445–1454.
  14.  Mora JR, Bono MR, Manjunath N, et al. Selective imprinting of gut-
homing T cells by Peyer’s patch dendritic cells. Nature. 2003;424: 
88–93.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
309
Importance of innate mucosal immunity
  15.  Ericsson A, Svensson M, Arya A, Agace WW. CCL25/CCR9 promotes 
the induction and function of CD103 on intestinal intraepithelial 
  lymphocytes. Eur J Immunol. 2004;34:2720–2729.
  16.  Kawamata N, Xu B, Nishijima H, et al. Expression of endothelia and 
lymphocyte adhesion molecules in bronchus-associated lymphoid tissue 
(BALT) in adult human lung. Respir Res. 2009;10:97.
  17.  Wilson CL, Ouellette AJ, Satchell DP, et al. Regulation of intestinal 
alpha-defensin activation by the metalloproteinase matrilysin in innate 
host defense. Science. 1999;286:113–117.
  18.  Heather LC, Cole MA, Lygate CA, et al. Fatty acid transporter levels 
and palmitate oxidation rate correlate with ejection fraction in the 
infarcted rat heart. Cardiovasc Res. 2006;72:430–437.
  19.  Heritage PL, Brook MA, Underdown BJ, McDermott MR. Intranasal 
immunization with polymer-grafted microparticles activates the nasal-
associated lymphoid tissue and draining lymph nodes. Immunology. 
1998;93:249–256.
  20.  Sheil B, Shanahan F, O’Mahony L. Probiotic effects on inflammatory 
bowel disease. J Nutr. 2007;137(3 Suppl 2):819S–824S.
  21.  Zhang SZ, Zhao XH, Zhang DC. Cellular and molecular immunop-
athogenesis of ulcerative colitis. Cell Mol Immunol. 2006;3:35–40.
  22.  Ramakrishnan K, Salinas RC. Peptic ulcer disease. Am Fam Physician. 
2007;76:1005–1012.
  23.  Candy DCA. Rotavirus infection: A systemic illness? Plos Med. 
2007;4:614–615.
  24.  Hyser JM, Estes MK. Rotavirus vaccines and pathogenesis: 2008. Curr 
Opin Gastroenterol. 2009;25:36–43.
  25.  Grimwood K, Lambert SB. Rotavirus vaccines: Opportunities and 
challenges. Hum Vaccin. 2009;5:57–69.
  26.  Goller JL, Dimitriadis A, Tan A, Kelly H, Marshall JA. Long-term 
features of norovirus gastroenteritis in the elderly. J Hosp Infect. 
2004;58:286–291.
  27.  Singh JC, Cruickshank SM, Newton DJ, et al. Toll-like receptor-
mediated responses of primary intestinal epithelial cells during the 
development of colitis. Am J Physiol Gastrointest Liver Physiol. 2005; 
288:G514–G524.
  28.  Pritt BS, Clark CG. Amebiasis. Mayo Clin Proc. 2008;83:1154–1159.
  29.  Salles JM, Moraes LA, Salles MC. Hepatic amebiasis. Braz J Infect 
Dis. 2003;7:96–110.
  30.  Viboud C, Alonso WJ, Simonsen L. Influenza in tropical regions. PLoS 
Med. 2006;3:e89.
  31.  D’Heilly SJ, Janoff EN, Nichol P, Nichol KL. Rapid diagnosis of 
influenza infection in older adults: Influence on clinical care in a routine 
clinical setting. J Clin Virol. 2008;42:124–128.
  32.  Jung WW, Chun T, Sul D, et al. Strategies against human papillomavirus 
infection and cervical cancer. J Microbiol. 2004;42:255–266.
  33.  Osen W, Jochmus I, Muller M, Gissmann L. Immunization against 
human papillomavirus infection and associated neoplasia. J Clin Virol. 
2000;19:75–78.
  34.  Adachi O, Kawai T, Takeda K, et al. Targeted disruption of the 
MyD88 gene results in loss of IL-1- and IL-18-mediated function. 
Immunity. 1998;9:143–150.
  35.  Sun L, Deng L, Ea CK, Xia ZP, Chen ZJ. The TRAF6 ubiquitin ligase 
and TAK1 kinase mediate IKK activation by BCL10 and MALT1 in 
T lymphocytes. Mol Cell. 2004;14:289–301.
  36.  Keating SE, Maloney GM, Moran EM, Bowie AG. IRAK-2 partici-
pates in multiple toll-like receptor signalling pathways to NFkappaB 
via activation of TRAF6 ubiquitination. J Biol Chem. 2007;282: 
33435–33443.
  37.  Gururajan M, Jacob J, Pulendran B. Toll-like receptor expression and 
responsiveness of distinct murine splenic and mucosal B-cell subsets. 
PLoS One. 2007;2:e863.
  38.  Ray A, Karmakar P, Biswas T. Up-regulation of CD80-CD86 and IgA 
on mouse peritoneal B-1 cells by porin of Shigella dysenteriae is Toll-
like receptors 2 and 6 dependent. Mol Immunol. 2004;41:1167–1175.
  39.  Cario E, Gerken G, Podolsky DK. Toll-like receptor 2 controls mucosal 
inflammation by regulating epithelial barrier function.   Gastroenterology. 
2007;132:1359–1374.
  40.  Girardin SE, Tournebize R, Mavris M, et al. CARD4/Nod1 mediates 
NF-kappaB and JNK activation by invasive Shigella flexneri. EMBO 
Rep. 2001;2:736–742.
  41.  Snellings NJ, Tall BD, Venkatesan MM. Characterization of Shigella 
type 1 fimbriae: Expression, FimA sequence, and phase variation. Infect 
Immun. 1997;65:2462–2467.
  42.  Zhang Y, Chen H, Yang L. Toll-like receptor 4 participates in gastric 
mucosal protection through Cox-2 and PGE2. Dig Liver Dis. 2010;42: 
472–476.
  43.  Matharu KS, Mizoguchi E, Cotoner CA, et al. Toll-like receptor 
4-mediated regulation of spontaneous Helicobacter-dependent colitis 
in IL-10-deficient mice. Gastroenterology. 2009;137:1380–1390.
  44.  Shang L, Fukata M, Thirunarayanan N, et al. Toll-like receptor sig-
nalling in small intestinal epithelium promotes B-cell recruitment 
and IgA production in lamina propria. Gastroenterology. 2008;135: 
529–538.
  45.  Schmausser B, Andrulis M, Endrich S, et al. Expression and subcel-
lular distribution of toll-like receptors TLR4, TLR5 and TLR9 on the 
gastric epithelium in Helicobacter pylori infection. Clin Exp Immunol. 
2004;136:521–526.
  46.  Gewirtz AT, Yu Y, Krishna US, Israel DA, Lyons SL, Peek RM Jr. 
Helicobacter pylori flagellin evades toll-like receptor 5-mediated innate 
immunity. J Infect Dis. 2004;189:1914–1920.
  47.  Takenaka R, Yokota K, Ayada K, et al. Helicobacter pylori heat-shock 
protein 60 induces inflammatory responses through the Toll-like 
receptor-triggered pathway in cultured human gastric epithelial cells. 
Microbiology. 2004;150(Pt 12):3913–3922.
  48.  Franchimont D, Vermeire S, El Housni H, et al. Deficient host-bacteria 
interactions in inflammatory bowel disease? The toll-like receptor 
(TLR)-4 Asp299 gly polymorphism is associated with Crohn’s disease 
and ulcerative colitis. Gut. 2004;53:987–992.
  49.  Lodes MJ, Cong Y, Elson CO, et al. Bacterial flagellin is a dominant 
antigen in Crohn disease. J Clin Invest. 2004;113:1296–1306.
  50.  Otte JM, Rosenberg IM, Podolsky DK. Intestinal myofibroblasts in 
innate immune responses of the intestine. Gastroenterology. 2003;124: 
1866–1878.
  51.  Maeda S, Hsu LC, Liu H, et al. Nod2 mutation in Crohn’s disease 
potentiates NF-kappaB activity and IL-1beta processing. Science. 
2005;307:734–738.
  52.  Maldonado C, Trejo W, Ramirez A, et al. Lipophosphopeptidoglycan 
of Entamoeba histolytica induces an antiinflammatory innate immune 
response and downregulation of toll-like receptor 2 (TLR-2) gene 
expression in human monocytes. Arch Med Res. 2000;31(4 Suppl): 
S71–S73.
  53.  Maldonado-Bernal C, Kirschning CJ, Rosenstein Y, et al. The innate 
immune response to Entamoeba histolytica lipopeptidophosphoglycan 
is mediated by toll-like receptors 2 and 4. Parasite Immunol. 2005;27: 
127–137.
  54.  Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like recep-
tors in spontaneous commensal-dependent colitis. Immunity. 
2006;25:319–329.
  55.  Lembo A, Kalis C, Kirschning CJ, et al. Differential contribution of 
Toll-like receptors 4 and 2 to the cytokine response to Salmonella 
enterica serovar Typhimurium and Staphylococcus aureus in mice. 
Infect Immun. 2003;71:6058–6062.
  56.  Andersen-Nissen E, Smith KD, Strobe KL, et al. Evasion of Toll-like 
receptor 5 by flagellated bacteria. Proc Natl Acad Sci U S A. 2005;102: 
9247–9252.
  57.  Vazquez-Torres A, Vallance BA, Bergman MA, et al. Toll-like recep-
tor 4 dependence of innate and adaptive immunity to   Salmonella: 
  Importance of the Kupffer cell network. J Immunol. 2004;172:   
6202–6208.
  58.  Hapfelmeier S, Stecher B, Barthel M, et al. The Salmonella patho-
genicity island (SPI)-2 and SPI-1 type III secretion systems allow 
  Salmonella serovar typhimurium to trigger colitis via MyD88-
  dependent and MyD88-independent mechanisms. J Immunol. 
2005;174: 1675–1685.International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
310
Dwivedy and Aich
  59.  Huang FC, Werne A, Li Q, Galyov EE, Walker WA, Cherayil BJ. 
Cooperative interactions between flagellin and SopE2 in the epithelial 
interleukin-8 response to Salmonella enterica serovar typhimurium 
infection. Infect Immun. 2004;72:5052–5062.
  60.  Raffatellu M, Chessa D, Wilson RP, Dusold R, Rubino S, Baumler AJ. 
The Vi capsular antigen of Salmonella enterica serotype Typhi reduces 
Toll-like receptor-dependent interleukin-8 expression in the intestinal 
mucosa. Infect Immun. 2005;73:3367–3374.
  61.  Jerke S, Srinivasan A, McSorley SJ. Expression of Toll/IL-1R domain-
containing adaptor protein (TIRAP) is detrimental to primary clearance 
of Salmonella and is not required for the generation of protective 
immunity. Immunol Lett. 2008;116:64–71.
  62.  Backhed F, Normark S, Schweda EK, Oscarson S, Richter-Dahlfors A. 
Structural requirements for TLR4-mediated LPS signalling: A bio  logical 
role for LPS modifications. Microbes Infect. 2003;5:1057–1063.
  63.  Steiner TS, Nataro JP, Poteet-Smith CE, Smith JA, Guerrant RL. Enteroag-
gregative Escherichia coli expresses a novel flagellin that causes IL-8 release 
from intestinal epithelial cells. J Clin Invest. 2000;105: 1769–1777.
  64.  Hajishengallis G, Tapping RI, Martin MH, et al. Toll-like receptor 2 
mediates cellular activation by the B subunits of type II heat-labile 
enterotoxins. Infect Immun. 2005;73:1343–1349.
  65.  Asai Y, Ohyama Y, Gen K, Ogawa T. Bacterial fimbriae and their 
peptides activate human gingival epithelial cells through Toll-like 
receptor 2. Infect Immun. 2001;69:7387–7395.
  66.  Hall JA, Bouladoux N, Sun CM, et al. Commensal DNA limits regula-
tory T cell conversion and is a natural adjuvant of intestinal immune 
responses. Immunity. 2008;29:637–649.
  67.  Ikeda T, Hiromatsu K, Hotokezaka M, Chijiiwa K. Up-regulation of intes-
tinal toll-like receptors and cytokine expressions change after TPN admin-
istration and a lack of enteric feeding. J Surg Res. 2010;160:244–252.
  68.  Tirumurugaan KG, Dhanasekaran S, Raj GD, Raja A, Kumanan K, 
Ramaswamy V. Differential expression of toll-like receptor mRNA 
in selected tissues of goat (Capra hircus). Vet Immunol Immunopathol. 
2010;133:296–301.
  69.  Hammerbeck DM, Burleson GR, Schuller CJ, et al. Administration of a 
dual toll-like receptor 7 and toll-like receptor 8 agonist protects against 
influenza in rats. Antiviral Res. 2007;73:1–11.
  70.  Hirano T, Kodama S, Moriyama M, Kawano T, Suzuki M. The role 
of Toll-like receptor 4 in eliciting acquired immune responses against 
nontypeable Haemophilus influenzae following intranasal immuniza-
tion with outer membrane protein. Int J Pediatr Otorhinolaryngol. 
2009;73:1657–1665.
  71.  Yamin M, Holbrook EH, Gray ST, et al. Cigarette smoke combined 
with Toll-like receptor 3 signalling triggers exaggerated epithelial 
regulated upon activation, normal T-cell expressed and secreted/
CCL5 expression in chronic rhinosinusitis. J Allergy Clin Immunol. 
2008;122:1145–1153.
  72.  Tulic MK, Fiset PO, Manoukian JJ, et al. Role of toll-like receptor 4 in 
protection by bacterial lipopolysaccharide in the nasal mucosa of atopic 
children but not adults. Lancet. 2004;363:1689–1697.
  73.  Sukkar MB, Xie S, Khorasani NM, et al. Toll-like receptor 2, 3, and 
4 expression and function in human airway smooth muscle. J Allergy 
Clin Immunol. 2006;118:641–648.
  74.  Wang J, Matsukura S, Watanabe S, Adachi M, Suzaki H. Involvement 
of Toll-like receptors in the immune response of nasal polyp epithelial 
cells. Clin Immunol. 2007;124:345–352.
  75.  Zhang Z, Bashiruddin JB, Doel C, Horsington J, Durand S,   
Alexandersen S. Cytokine and Toll-like receptor mRNAs in the nasal-
associated lymphoid tissues of cattle during foot-and-mouth disease 
virus infection. J Comp Pathol. 2006;134:56–62.
  76.  Muir A, Soong G, Sokol S, et al. Toll-like receptors in normal and cystic 
fibrosis airway epithelial cells. Am J Respir Cell Mol Biol. 2004;30: 
777–783.
  77.  Pabst R, Durak D, Roos A, Luhrmann A, Tschernig T. TLR2/6 stimula-
tion of the rat lung: Effects on lymphocyte subsets, natural killer cells 
and dendritic cells in different parts of the air-conducting compartments 
and at different ages. Immunology. 2009;126:132–139.
  78.  Lane AP, Truong-Tran QA, Schleimer RP. Altered expression of genes 
associated with innate immunity and inflammation in recalcitrant rhi-
nosinusitis with polyps. Am J Rhinol. 2006;20:138–144.
  79.  Asplin IR, Carl DJ, Way SS, Jones AL. Role of Toll-like receptor 2 in 
innate resistance to Group B Streptococcus. Microb Pathog. 2008;44: 
43–51.
  80.  Song JJ, Cho JG, Woo JS, Lee HM, Hwang SJ, Chae SW. Differential 
expression of toll-like receptors 2 and 4 in rat middle ear. Int J Pediatr 
Otorhinolaryngol. 2009;73:821–824.
  81.  Allam JP, Peng WM, Appel T, et al. Toll-like receptor 4 ligation 
enforces tolerogenic properties of oral mucosal Langerhans cells.   
J Allergy Clin Immunol. 2008;121:368–374.
  82.  Ferwerda G, Netea MG, Joosten LA, van der Meer JW, Romani L, 
Kullberg BJ. The role of Toll-like receptors and C-type lectins for 
  vaccination against Candida albicans. Vaccine. 2010;28:614–622.
  83.  John PS, Andrea E, Cecilia E, et al. 586 toll-like receptor 3 (TLR3) 
signaling improves intestinal mucosal defense against pathogens. 
Gastroenterology. 2009;136:A93–A94.
  84.  Srinivasan M, Kodumudi KN, Zunt SL. Soluble CD14 and toll-like 
receptor-2 are potential salivary biomarkers for oral lichen planus and 
burning mouth syndrome. Clin Immunol. 2008;126:31–37.
  85.  Yuan ZQ, Bennett L, Campo MS, Nasir L. Bovine papillomavirus 
type 1 E2 and E7 proteins down-regulate toll like receptor 4 (TLR4) 
expression in equine fibroblasts. Virus Res. 2010;149:124–127.
  86.  Ghosh M, Schaefer TM, Fahey JV, Wright JA, Wira CR. Antiviral 
responses of human Fallopian tube epithelial cells to toll-like receptor 
3 agonist poly(I:C). Fertil Steril. 2008;89(5 Suppl):1497–1506.
  87.  Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, 
  Flavell RA, Oldstone MB. Does Toll-like receptor 3 play a biological 
role in virus infections? Virology. 2004;322:231–238.
  88.  Glass RI, Noel J, Ando T, et al. The epidemiology of enteric calici-
viruses from humans: A reassessment using new diagnostics. J Infect 
Dis. 2000;181 Suppl 2:S254–S261.
  89.  Rindsjo E, Holmlund U, Sverremark-Ekstrom E, Papadogiannakis N, 
Scheynius A. Toll-like receptor-2 expression in normal and pathologic 
human placenta. Hum Pathol. 2007;38:468–473.
  90.  Vijay-Kumar M, Aitken JD, Carvalho FA, et al. Metabolic syndrome 
and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 
2010;328:228–231.
  91.  Chung SH, Nam KH, Kweon MN. Staphylococcus aureus accelerates an 
experimental allergic conjunctivitis by Toll-like receptor 2-dependent 
manner. Clin Immunol. 2009;131:170–177.
  92.  Genc MR, Vardhana S, Delaney ML, et al. Relationship between a 
toll-like receptor-4 gene polymorphism, bacterial vaginosis-related 
flora and vaginal cytokine responses in pregnant women. Eur J Obstet 
Gynecol Reprod Biol. 2004;116:152–156.
  93.  Zariffard MR, Harwani S, Novak RM, Graham PJ, Ji X, Spear GT. 
Trichomonas vaginalis infection activates cells through toll-like 
receptor 4. Clin Immunol. 2004;111:103–107.
  94.  Chamaillard M, Hashimoto M, Horie Y, et al. An essential role for 
NOD1 in host recognition of bacterial peptidoglycan containing 
diaminopimelic acid. Nat Immunol. 2003;4:702–707.
  95.  Girardin SE, Boneca IG, Carneiro LA, et al. Nod1 detects a unique 
muropeptide from gram-negative bacterial peptidoglycan. Science. 
2003;300:1584–1587.
  96.  Kobayashi K, Inohara N, Hernandez LD, et al. RICK/Rip2/CARDIAK 
mediates signalling for receptors of the innate and adaptive immune 
systems. Nature. 2002;416:194–199.
  97.  Inohara N, Koseki T, Lin J, et al. An induced proximity model for 
  NF-kappa B activation in the Nod1/RICK and RIP signalling pathways. 
J Biol Chem. 2000;275:27823–27831.
  98.  Kobayashi KS, Chamaillard M, Ogura Y, et al. Nod2-dependent regu-
lation of innate and adaptive immunity in the intestinal tract. Science. 
2005;307:731–734.
  99.  Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 
associated with susceptibility to Crohn’s disease. Nature. 2001;411: 
603–606.International Journal of General Medicine
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/international-journal-of-general-medicine-journal
The International Journal of General Medicine is an international, 
peer-reviewed open-access journal that focuses on general and internal 
medicine, pathogenesis, epidemiology, diagnosis, monitoring and treat-
ment protocols. The journal is characterized by the rapid reporting of 
reviews, original research and clinical studies across all disease areas. 
A key focus is the elucidation of disease processes and management 
protocols resulting in improved outcomes for the patient.The manu-
script management system is completely online and includes a very 
quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.
International Journal of General Medicine 2011:4 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
Dovepress
311
Importance of innate mucosal immunity
  100.  Hysi P, Kabesch M, Moffatt MF, et al. NOD1 variation, immunoglobulin 
E and asthma. Hum Mol Genet. 2005;14:935–941.
  101.  Eckmann L. Sensor molecules in intestinal innate immunity against 
bacterial infections. Curr Opin Gastroenterol. 2006;22:95–101.
  102.  Tohno M, Ueda W, Azuma Y, et al. Molecular cloning and func-
tional characterization of porcine nucleotide-binding oligomerization 
domain-2 (NOD2). Mol Immunol. 2008;45:194–203.
  103.  Luciano F, Krajewska M, Ortiz-Rubio P, et al. Nur77 converts phe-
notype of Bcl-B, an antiapoptotic protein expressed in plasma cells 
and myeloma. Blood. 2007;109:3849–3855.
  104.  Boyden ED, Dietrich WF. Nalp1b controls mouse macrophage sus-
ceptibility to anthrax lethal toxin. Nat Genet. 2006;38:240–244.
  105.  Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-
  associated uric acid crystals activate the NALP3 inflammasome. 
Nature. 2006;440:237–241.
  106.  Yoneyama M, Fujita T. Function of RIG-I-like receptors in antiviral 
innate immunity. J Biol Chem. 2007;282:15315–15318.
  107.  Kato H, Sato S, Yoneyama M, et al. Cell type-specific involvement of 
RIG-I in antiviral response. Immunity. 2005;23:19–28.
  108.  Kawai T, Takahashi K, Sato S, et al. IPS-1, an adaptor triggering 
RIG-I- and Mda5-mediated type I interferon induction. Nat Immunol. 
2005;6:981–988.
  109.  Saha SK, Pietras EM, He JQ, et al. Regulation of antiviral responses by 
a direct and specific interaction between TRAF3 and Cardif. EMBO J. 
2006;25:3257–3263.
  110.  Sasai M, Shingai M, Funami K, et al. NAK-associated protein 1 
participates in both the TLR3 and the cytoplasmic pathways in type I 
IFN induction. J Immunol. 2006;177:8676–8683.
  111.  Yoneyama M, Kikuchi M, Matsumoto K, et al. Shared and unique 
functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in 
antiviral innate immunity. J Immunol. 2005;175:2851–2858.
  112.  Wang X, Li M, Zheng H, et al. Influenza A virus NS1 protein pre-
vents activation of NF-kappaB and induction of alpha/beta interferon.   
J Virol. 2000;74:11566–11573.
  113.  Wang Y, Zhang HX, Sun YP, et al. Rig-I-/- mice develop colitis associ-
ated with downregulation of G alpha i2. Cell Res. 2007;17:858–868.
  114.  Rohrl J, Yang D, Oppenheim JJ, Hehlgans T. Specific binding and 
chemotactic activity of mBD4 and its functional orthologue hBD2 to 
CCR6-expressing cells. J Biol Chem. 2010;285:7028–7034.
  115.  Bachman MA, Miller VL, Weiser JN. Mucosal lipocalin 2 has pro-
inflammatory and iron-sequestering effects in response to bacterial 
enterobactin. PLoS Pathog. 2009;5:e1000622.
  116.  Schauber J, Gallo RL. Antimicrobial peptides and the skin immune 
defense system. J Allergy Clin Immunol. 2008;122:261–266.
  117.  Guo X, Rosa AJ, Chen DG, Wang X. Molecular mechanisms of primary 
and secondary mucosal immunity using avian infectious bronchitis virus 
as a model system. Vet Immunol Immunopathol. 2008;121:332–343.
  118.  Bevins CL, Martin-Porter E, Ganz T. Defensins and innate host defence 
of the gastrointestinal tract. Gut. 1999;45:911–915.
  119.  Skwor TA, Atik B, Kandel RP, Adhikari HK, Sharma B, Dean D. Role of 
secreted conjunctival mucosal cytokine and chemokine proteins in differ-
ent stages of trachomatous disease. PLoS Negl Trop Dis. 2008;2:e264.
  120.  Zhaori G, Sun M, Ogra PL. Characteristics of the immune response 
to poliovirus virion polypeptides after immunization with live or 
inactivated polio vaccines. J Infect Dis. 1988;158:160–165.
  121.  Wu HY, Weiner HL. Oral tolerance. Immunol Res. 2003;28:265–284.